Safety and immunogenicity of an inactivated whole cell tuberculosis vaccine booster in adults primed with BCG: A randomized, controlled trial of DAR-901

BACKGROUND: Development of a tuberculosis vaccine to boost BCG is a major international health priority. SRL172, an inactivated whole cell booster derived from a non-tuberculous mycobacterium, is the only new vaccine against tuberculosis to have demonstrated efficacy in a Phase 3 trial. In the prese...

Descripción completa

Detalles Bibliográficos
Autores principales: von Reyn, C. Fordham, Lahey, Timothy, Arbeit, Robert D., Landry, Bernard, Kailani, Leway, Adams, Lisa V., Haynes, Brenda C., Mackenzie, Todd, Wieland-Alter, Wendy, Connor, Ruth I., Tvaroha, Sue, Hokey, David A., Ginsberg, Ann M., Waddell, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5429024/
https://www.ncbi.nlm.nih.gov/pubmed/28498853
http://dx.doi.org/10.1371/journal.pone.0175215

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5429024/
https://www.ncbi.nlm.nih.gov/pubmed/28498853
http://dx.doi.org/10.1371/journal.pone.0175215

Ejemplares similares